Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.61 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.56 |
| ▸ | ANPEP | P15144 | 2/20 | 0.53 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.49 |
| ▸ | ALPI | P09923 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | XIAP | P98170 | 1/20 | 0.47 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | SCN4A | P35499 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7195304 | 1.00 | EPHX1 (0.61) | EPHX1CSNK1EANPEPSLC15A1ALPI | |
| SCHEMBL7308044 | 1.00 | EPHX1 (0.61) | EPHX1CSNK1EANPEPSLC15A1ALPI | |
| SCHEMBL30025452 | 1.00 | EPHX1 (0.61) | EPHX1CSNK1EANPEPSLC15A1ALPI | |
| SCHEMBL7797835 | 1.00 | EPHX1 (0.61) | EPHX1CSNK1EANPEPSLC15A1ALPI | |
| Hydrochloric Acid SCHEMBL7499120 | 0.98 | EPHX1 (0.59) | EPHX1CSNK1EANPEPSLC15A1ALPI | |
| Hydrochloric Acid SCHEMBL7095630 | 0.98 | EPHX1 (0.59) | EPHX1CSNK1EANPEPSLC15A1ALPI | |
| Hydrochloric Acid SCHEMBL8947219 | 0.98 | EPHX1 (0.59) | EPHX1CSNK1EANPEPSLC15A1ALPI | |
| Hydrochloric Acid SCHEMBL8972242 | 0.98 | EPHX1 (0.59) | EPHX1CSNK1EANPEPSLC15A1ALPI | |
| SCHEMBL8233707 | 0.91 | EPHX1 (0.52) | EPHX1CSNK1EANPEPSLC15A1ALPI | |
| Hydrochloric Acid SCHEMBL5839457 | 0.88 | CSNK1E (0.53) | EPHX1CSNK1EANPEPSLC6A2TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1302468-A1 | Processes and intermediates for manufacturing retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 2003-04-16 | — | — | EP | claimed |
| EP-0748801-B1 | 2-ISOXAZOLINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME, AND PROCESS FOR PRODUCING RELATED DERIVATIVES FROM THE SAME | DAICEL CHEM (JP) | 2001-12-19 | — | — | EP | claimed |
| EP-1090914-A2 | Processes and intermediates for manufacturing retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 2001-04-11 | — | — | EP | claimed |
| EP-0486948-B1 | Retroviral protease inhibiting compounds | ABBOTT LAB (US) | 2000-10-04 | — | — | EP | claimed |
| US-5837873-A | PROTECTED OXYDIAMINES | ABBOTT LABORATORIES (US) | 1998-11-17 | — | — | US | claimed |
| US-5659045-A | AIDS THERAPY | ABBOTT LABORATORIES (US) | 1997-08-19 | — | — | US | claimed |
| EP-0727419-A2 | Retroviral protease inhibiting compounds | Abbott Laboratories (US) | 1996-08-21 | — | — | EP | claimed |
| US-20140194349-A1 | HIV Protease Inhibiting Compounds | ABBVIE INC. (US) | 2014-07-10 | — | — | US | disclosed |
| EP-1697344-B1 | HIV PROTEASE INHIBITING COMPOUNDS | ABBOTT LAB (US) | 2011-09-28 | — | — | EP | disclosed |
| EP-2266971-A2 | Hiv protease inhibiting compounds | Abbott Laboratories (US) | 2010-12-29 | — | — | EP | disclosed |
| US-7834043-B2 | Prevent reproduct of aids virus | ABBOTT LABORATORIES (US) | 2010-11-16 | — | — | US | disclosed |
| US-20100249181-A1 | HIV Protease Inhibiting Compounds | ABBOTT LABORATORIES (US) | 2010-09-30 | — | — | US | disclosed |
| EP-1302468-B1 | Processes and intermediates for manufacturing retroviral protease inhibiting compounds | ABBOTT LAB (US) | 2008-12-17 | — | — | EP | disclosed |
| EP-0672649-A1 | Process for producing optically active diaminohexanone derivative | Takasago International Corporation (JP) | 1995-09-20 | — | — | EP | disclosed |
| WO-1995020384-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING HIV PROTEASE INHIBITORS | ABBOTT LABORATORIES (US) | 1995-08-03 | — | — | WO | disclosed |
| WO-1995009614-A1 | PHARMACEUTICAL COMPOSITION | ABBOTT LABORATORIES (US) | 1995-04-13 | — | — | WO | disclosed |
| WO-1995007696-A1 | PHARMACEUTICAL COMPOSITION OF HIV-PROTEASE INHIBITORS | ABBOTT LABORATORIES (US) | 1995-03-23 | — | — | WO | disclosed |
| US-5354866-A | Treating HIV infections | ABBOTT LABORATORIES (US) | 1994-10-11 | — | — | US | disclosed |
| WO-1994014436-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 1994-07-07 | — | — | WO | disclosed |
| EP-0486948-A2 | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 1992-05-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249181-A1 | HIV Protease Inhibiting Compounds | SERPINB1, HPN, DNPEP | EPHX1 2053/4885CSNK1E 1502/4885ANPEP 11/4885 |
| US-20140194349-A1 | HIV Protease Inhibiting Compounds | SERPINB1, HPN, DNPEP | EPHX1 2053/4885CSNK1E 1502/4885ANPEP 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.